TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11726252

Group type: EXPERIMENTAL
Intervention: 5RM bench press before explosive push-ups
Number of subjects: 0

Group type: COMPARATOR
Intervention: Explosive push-ups only
Number of subjects: 0
Study: 9003214

Group type: EXPERIMENTAL
Intervention: Air at 37 degrees C and 90% RH
Number of subjects: 10

Group type: COMPARATOR
Intervention: Air at 20 degrees C and 30% RH
Number of subjects: 10
Study: 8305125

Group type: EXPERIMENTAL
Intervention: CRH plus TRH administration
Number of subjects: 28

Group type: COMPARATOR
Intervention: CRH alone
Number of subjects: 28
Study: 3423736

Group type: EXPERIMENTAL
Intervention: Cigarette smoking without cimetidine pretreatment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cigarette smoking after cimetidine pretreatment (2 X 400 mg orally for 2 days and 400 mg orally 1.5 h before examination)
Number of subjects: 14
Study: 30986958

Group type: EXPERIMENTAL
Intervention: Pistachios (56 g, 1318 kJ)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Savory biscuits (56 g, isoenergetic/equiprotein)
Number of subjects: 30
Study: 28196772

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Group therapy (ACT‐G)
Number of subjects: 126
Study: 26688585

Group type: EXPERIMENTAL
Intervention: Simulation first (90 students)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Clinic first (90 students)
Number of subjects: 180
Study: 23706025

Group type: EXPERIMENTAL
Intervention: Robot-assisted walking training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study: 21592186

Group type: EXPERIMENTAL
Intervention: Cryotherapy gel wrap applied to lower leg skin for 30 minutes daily for four weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care (compression and leg elevation)
Number of subjects: 60
Study: 18269390

Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Starch solutions
Number of subjects: 40
Study: 17278430

Group type: EXPERIMENTAL
Intervention: Chemotherapy (one course) for group B patients
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Total chemotherapy for group B patients
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Group B patients (AML other than APL)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Group A patients (APL)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Total AML patients
Number of subjects: 141
Study: 15218815

Group type: EXPERIMENTAL
Intervention: Baseline and annual MRI evaluation
Number of subjects: 0
Study: 11720698

Group type: EXPERIMENTAL
Intervention: Clinician's choice design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Equipoise stratified design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Completely randomized designs
Number of subjects: 0
Study: 8988796

Group type: EXPERIMENTAL
Intervention: AMPT with full-strength tryptophan-depleting amino acid drink
Number of subjects: 8

Group type: COMPARATOR
Intervention: AMPT with tryptophan-supplemented amino acid drink
Number of subjects: 8

Group type: COMPARATOR
Intervention: AMPT with 25% strength tryptophan-depleting amino acid drink
Number of subjects: 8
Study: 8491007

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg daily)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Coumadin (with heparin until oral anticoagulation established)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo (with discontinuation of heparin)
Number of subjects: 300
Study: 3574990

Group type: EXPERIMENTAL
Intervention: Nebulized racemic epinephrine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Warmed, humidified gas
Number of subjects: 45
Study: 30217640

Group type: EXPERIMENTAL
Intervention: Vasoactive medications
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Duration of vasoactive medication use (in days)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Cumulative norepinephrine dose (μg/kg/d)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Vasopressin
Number of subjects: 172

Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 172
Study: 26888712

Group type: EXPERIMENTAL
Intervention: DIET (25% daily needs energy deficits induced by diet only)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: EX (25% daily needs energy deficits induced by exercise only)
Number of subjects: 10
Study: 24913338

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 12
Study: 22081005

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Losartan + Simvastatin (20 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amlodipine + Simvastatin (20 mg/day)
Number of subjects: 0
Study: 20171410

Group type: EXPERIMENTAL
Intervention: Carbomer-based lipid-containing gel (CBLC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: HP-guar gel
Number of subjects: 30
Study: 18165396

Group type: EXPERIMENTAL
Intervention: Raloxifene (180 mg daily)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 11576046

Group type: COMPARATOR
Intervention: bupivacaine 0.5% plain
Number of subjects: 200

Group type: COMPARATOR
Intervention: bupivacaine 0.5% plus hyaluronidase 100 i.u. ml‐1
Number of subjects: 200

Group type: COMPARATOR
Intervention: lidocaine 2% plus epinephrine 1:200 000
Number of subjects: 200

Group type: COMPARATOR
Intervention: mixture of lidocaine 2% and bupivacaine 0.5% (2:3 volume per volume) containing hyaluronidase 25 i.u. ml‐1
Number of subjects: 200
Study: 9581985

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (150 mg caffeine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1000 kcal meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 12
Study: 8140940

Group type: EXPERIMENTAL
Intervention: NaF at 75 mg/day
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 3395500

Group type: EXPERIMENTAL
Intervention: Weekly prescription for BSE
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Every-two-weeks prescription for BSE
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Monthly prescription for BSE
Number of subjects: 51
Study: 29891419

Group type: EXPERIMENTAL
Intervention: 3M True Definition Scanner (TDS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: cara TRIOS (Trios)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Impregum Penta Soft (Impregum)
Number of subjects: 30
Study: 28626213

Group type: EXPERIMENTAL
Intervention: Imrecoxib 200 mg twice daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Imrecoxib
Number of subjects: 60

Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 60
Study: 24978157

Group type: EXPERIMENTAL
Intervention: Education-support intervention delivered in the home setting for 9 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 50
Study: 23747130

Group type: EXPERIMENTAL
Intervention: Thick latex surgical gloves
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional gloves
Number of subjects: 70
Study: 21194988

Group type: EXPERIMENTAL
Intervention: Puncture site at lateral malleolar part of the SSV (Group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Puncture site at mid-calf (Group 2)
Number of subjects: 60
Study: 19083555

Group type: EXPERIMENTAL
Intervention: Reduction mammaplasty
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 100
Study: 16575010

Group type: EXPERIMENTAL
Intervention: Fludarabine (25 mg/m2 IV daily for 5 days every 4 weeks)
Number of subjects: 381

Group type: COMPARATOR
Intervention: CVP (cyclophosphamide 750 mg/m2 IV on day 1; vincristine 1.4 mg/m2 IV on day 1; prednisone 40 mg/m2 orally on days 1-5 every 4 weeks)
Number of subjects: 381
Study: 12742332

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg)
Number of subjects: 3294

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3294
Study: 10690763

Group type: EXPERIMENTAL
Intervention: Conventional insemination (25,000 sperm, prolonged contact 16-24 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short insemination protocol (25,000 sperm, limited to 2 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intracytoplasmic sperm injection (ICSI, 1 sperm injected)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Frozen embryo transfer (ET)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fresh embryo transfer (ET)
Number of subjects: 0
Study: 9139174

Group type: EXPERIMENTAL
Intervention: 10 g of hot red pepper
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard meal without hot red pepper (control)
Number of subjects: 0
Study: 8444361

Group type: EXPERIMENTAL
Intervention: Surgery based on prism-adapted angle (32 patients)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Surgery based on initially measured angle (31 patients)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Surgery based on angle before prism correction (14 patients)
Number of subjects: 77
Study: 30626253

Group type: EXPERIMENTAL
Intervention: Pegaspargase given intravenously
Number of subjects: 0
Study: 29735470

Group type: EXPERIMENTAL
Intervention: Oral ulcer powder combined with Kangfuxin liquid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 26677992

Group type: EXPERIMENTAL
Intervention: Patient Therapeutic Education (PTE)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 54
Study: 25558700

Group type: EXPERIMENTAL
Intervention: Knee SPECT scan
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Knee MRI
Number of subjects: 193

Group type: COMPARATOR
Intervention: Comparison with arthroscopy (gold standard)
Number of subjects: 193
Study: 22759259

Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite (CaHA) injections
Number of subjects: 116
Study: 21180368

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 448

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 448
Study: 18190562

Group type: EXPERIMENTAL
Intervention: Cross-linked collagen membranes (CLM)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Non-cross-linked collagen membranes (NCLM)
Number of subjects: 52
Study: 16731465

Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing (DDDR)
Number of subjects: 2010

Group type: COMPARATOR
Intervention: Ventricular pacing (VVIR)
Number of subjects: 2010
Study: 12595874

Group type: EXPERIMENTAL
Intervention: Transcranial electrostimulation treatment (TCET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study: 11013193

Group type: EXPERIMENTAL
Intervention: Topical diclofenac sodium 0.1% (20 patients)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dexamethasone 0.1% (20 patients)
Number of subjects: 40
Study: 8628597

Group type: EXPERIMENTAL
Intervention: Lovastatin 10 mg/d
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg/d
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Lovastatin 30 mg/d
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg/d
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Lovastatin (all doses)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 69
Study: 1484946

Group type: EXPERIMENTAL
Intervention: Ice/slush topical hypothermia (Group I)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No topical hypothermia (Group II)
Number of subjects: 100
Study: 3883733

Group type: EXPERIMENTAL
Intervention: 2 mg of molsidomine three times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 mg of molsidomine six times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4 mg of molsidomine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 8 mg of sustained-release molsidomine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4 mg of molsidomine four times daily
Number of subjects: 0
Study: 31696739

Group type: EXPERIMENTAL
Intervention: Levcromakalim
Number of subjects: 0
Study: 30048057

Group type: EXPERIMENTAL
Intervention: ERL (Er:YAG laser) with 40 mJ energy, 40 Hz frequency, fluence of 63.66 J/cm2
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: SRP + PDT (635 nm diode laser, 12 J energy, 30 s irradiation, Toluidine Blue PS application for 60 s)
Number of subjects: 84

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 84
Study: 26888217

Group type: EXPERIMENTAL
Intervention: Everolimus (starting dose 1.5 mg/day; C0 3‐8 ng/mL) with cyclosporine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Everolimus (starting dose 3 mg/day; C0 3‐8 ng/mL) with tacrolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mycophenolic acid (1.44 g/day or 2 g/day) with tacrolimus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exploratory objectives
Number of subjects: 0
Study: 25277457

Group type: EXPERIMENTAL
Intervention: Point-of-care C-reactive protein test
Number of subjects: 6500

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6500
Study: 22368149

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 5059

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5059

Group type: EXPERIMENTAL
Intervention: Clopidogrel in Atrial Fibrillation patients
Number of subjects: 5059
Study: 21142632

Group type: EXPERIMENTAL
Intervention: Erythropoietin therapy (50 IU/kg/week) for 2 weeks
Number of subjects: 0
Study: 17705013

Group type: EXPERIMENTAL
Intervention: Pelvic SPECT performed directly after normal void (Group I)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pelvic SPECT preceded by IV injection of 0.5 mg/kg furosemide and IV infusion of 500 cc saline (Group II)
Number of subjects: 30
Study: 15728297

Group type: EXPERIMENTAL
Intervention: L-arginine administered intravenously at the acute phase or orally at the interictal phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral administration of L-arginine within 30 minutes of a stroke
Number of subjects: 0
Study: 11927706

Group type: EXPERIMENTAL
Intervention: Carnitine supplementation (30 mg/kg/d)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (TPN without supplemental carnitine)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Carnitine supplementation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 9452282

Group type: EXPERIMENTAL
Intervention: Treated mosquito nets and dapsone/pyrimethamine (d/p) prophylaxis
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Treated mosquito nets
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Dapsone/pyrimethamine (d/p) prophylaxis
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Control group (no nets)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Treated mosquito nets and d/p prophylaxis (combined)
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: Treated mosquito nets and d/p prophylaxis
Number of subjects: 1800
Study: 7610591

Group type: EXPERIMENTAL
Intervention: Topical non-selective and selective beta-adrenoceptor antagonists
Number of subjects: 16
Study: 2116265

Group type: EXPERIMENTAL
Intervention: Intravenous nutrition (IVN) support
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no intravenous nutrition)
Number of subjects: 12
Study: 216027

Group type: EXPERIMENTAL
Intervention: 15 mg MSH/ACTH4-10
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 30 mg MSH/ACTH4-10
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31059955

Group type: COMPARATOR
Intervention: EBRT alone
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: EBRT + HDR-BTb
Number of subjects: 204
Study: 27893331

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 26624212

Group type: EXPERIMENTAL
Intervention: EGb761
Number of subjects: 2854

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2854
Study: 24072634

Group type: EXPERIMENTAL
Intervention: Micronized progesterone combined with transdermal oestradiol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate combined with transdermal oestradiol
Number of subjects: 0
Study: 21802121

Group type: EXPERIMENTAL
Intervention: Bipolar plasma vaporization of the prostate (BPVP)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection in saline (TURis)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate (TURP)
Number of subjects: 510
Study: 18931824

Group type: EXPERIMENTAL
Intervention: TG4010 10(8) pfu weekly for 6 weeks, then every 3 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TG4010 10(8) pfu every 3 weeks
Number of subjects: 40
Study: 16393600

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream once daily for 1 month after curettage and electrodesiccation (C&D)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle cream once daily for 1 month after curettage and electrodesiccation (C&D)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 20
Study: 12744914

Group type: EXPERIMENTAL
Intervention: Smoking intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 120
Study: 11060828

Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride
Number of subjects: 1400

Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride with statins (lovastatin, simvastatin, atorvastatin)
Number of subjects: 1400
Study: 8828781

Group type: COMPARATOR
Intervention: Injection of rHuEPO into the venous drip chamber using the Fresenius delivery system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injection of rHuEPO into the venous port
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Injection of rHuEPO into the venous drip chamber
Number of subjects: 0
Study: 1444083

Group type: EXPERIMENTAL
Intervention: Topical atropine immediately after trabeculectomy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Topical atropine beginning treatment on the first postoperative day
Number of subjects: 38
Study: 3894258

Group type: EXPERIMENTAL
Intervention: tiaprofenic acid (600 mg daily)
Number of subjects: 77

Group type: COMPARATOR
Intervention: ibuprofen (1.2 g daily)
Number of subjects: 77
Study: 31387082

Group type: EXPERIMENTAL
Intervention: Moderate-intensity resistance exercise
Number of subjects: 42

Group type: COMPARATOR
Intervention: High-intensity resistance exercise
Number of subjects: 42
Study: 31272982

Group type: EXPERIMENTAL
Intervention: Shield-only protection (shield group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shield and overlapping 0.5 mm Pb panel curtain (curtain group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shield, curtain and additional 75×40 cm, 0.5 mm Pb drape (drape group)
Number of subjects: 0
Study: 28650195

Group type: EXPERIMENTAL
Intervention: Mindfulness-based addiction treatment (MBAT)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 412
Study: 25271396

Group type: EXPERIMENTAL
Intervention: Expressive Writing (EW)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control Writing (CW)
Number of subjects: 193
Study: 23118269

Group type: EXPERIMENTAL
Intervention: Benzathine penicillin
Number of subjects: 82
Study: 21607954

Group type: EXPERIMENTAL
Intervention: Oseltamivir with milk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oseltamivir with water
Number of subjects: 0
Study: 19372711

Group type: EXPERIMENTAL
Intervention: HX575 (recombinant human epoetin alfa)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Epoetin alfa (active control)
Number of subjects: 114
Study: 16983472

Group type: EXPERIMENTAL
Intervention: Commercial graft (Ultrapro)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Nylon mosquito net
Number of subjects: 35
Study: 15284073

Group type: EXPERIMENTAL
Intervention: L‐NMMA (3 mg/kg during the initial 5 min and subsequent continuous infusion of 50 mug.kg(‐1).min(‐1) in saline)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Vehicle (saline)
Number of subjects: 9
Study: 11386492

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg/day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Nefazodone (400 mg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 9072590

Group type: EXPERIMENTAL
Intervention: Finasteride (5 alpha-reductase inhibitor)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no family history of BPH)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Familial BPH
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Familial BPH and sporadic BPH
Number of subjects: 69
Study: 7960166

Group type: EXPERIMENTAL
Intervention: 2000 ppm F NaF
Number of subjects: 5474

Group type: EXPERIMENTAL
Intervention: 2000 ppm F SMFP
Number of subjects: 5474
Study: 2853227

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 10
Study: 29446445

Group type: EXPERIMENTAL
Intervention: Lenograstim 5 µg/kg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Biosimilar filgrastim 10 µg/kg
Number of subjects: 42
Study: 27605969

Group type: EXPERIMENTAL
Intervention: Aerobic exercise on treadmill and diet
Number of subjects: 80

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 80
Study: 25047675

Group type: EXPERIMENTAL
Intervention: pemetrexed/cisplatin plus CBP501 25mg/m2 IV (Arm A)
Number of subjects: 63

Group type: COMPARATOR
Intervention: pemetrexed/cisplatin alone (Arm B)
Number of subjects: 63
Study: 23738680

Group type: EXPERIMENTAL
Intervention: Acupuncture (group A)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control (group B)
Number of subjects: 143
Study: 21150554

Group type: EXPERIMENTAL
Intervention: Ad5-seropositive individuals
Number of subjects: 889

Group type: COMPARATOR
Intervention: Ad5-seronegative individuals
Number of subjects: 889